Great Basin is developing the Staph ID/R Blood Culture Panel which is a rapid, automated, DNA multiplex assay for simultaneous identification of Staphylococcus aureus and Staphylococcus species and the detection of mecA gene directly from positive blood cultures.
The Great Basin advantage is that our results can provide species information. Nearly one third of all positive blood cultures are contaminants—such as CoNS (Coagulase Negative Staphylococcus)—from inadequate skin or catheter lumen cleaning or during blood draw. The likelihood CoNS is a true infection increases with the number of positive blood cultures determined to be GPCC by gram stain. The use of our test should provide >99% PPV after only two blood draws speeding the diagnosis and appropriate treatment.
Sepsis strikes 750,000 people annually in the US with high mortality rates and the leading cause are Staphylococcal blood stream infections. Timely diagnosis is critical to direct appropriate therapeutic choices. Current culture-based methods for gram positive blood culture bottles require 18-48 hours after the automated culture system alarms positive. As a result, clinicians often employ empiric treatment approaches which are often incorrect leading to longer lengths of stay and higher treatment costs.
The advantages of early diagnosis and treatment include: